Pelthos Therapeutics Inc. (PTHS)Healthcare | Biotechnology | Durham, United States | NYSE American
26.25 USD
-0.30
(-1.130%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 26.25 |
Hot Take ↕ | July 11, 2026, 4:14 a.m. EDT
The short-term outlook remains neutral despite a recent price dip, as the asset trades near its 50-day moving average with no clear momentum breakout or breakdown. The statistical forecast offers only a weak lean upward, which is insufficient to generate a bullish bias given the high volatility and lack of technical confirmation. For the long term, the picture is mixed: while the business shows a strong one-year price rally (+45%) and analysts offer a 'strong buy' rating with a significant upside target, the fundamentals are severely compromised by negative earnings, negative free cash flow, and a debt-to-equity ratio exceeding 150%. This heavy leverage and cash burn create a precarious balance sheet that prevents a top-tier investment rating, even though the recent price action suggests the market is currently optimistic about future catalysts. There is no dividend income to offset these risks. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.040416 |
| AutoETS | 0.074148 |
| MSTL | 0.074259 |
| AutoARIMA | 0.074902 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 3.18 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.430 |
| Excess Kurtosis | -0.88 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 150.792 |
| Revenue per Share | 10.841 |
| Market Cap | 91,235,680 |
| Forward P/E | -12.35 |
| Beta | 3.13 |
| Profit Margins | -186.23% |
| Previous Name | Chromocell Therapeutics Corporation |
| Website | https://pelthos.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.2447257 |
| Address1 | 4,020 Stirrup Creek Drive |
| Address2 | Suite 110 |
| All Time High | 60.0 |
| All Time Low | 4.5 |
| Ask | 0.0 |
| Ask Size | 200 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 27,740 |
| Average Daily Volume3 Month | 22,401 |
| Average Volume | 22,401 |
| Average Volume10Days | 27,740 |
| Beta | 3.131 |
| Bid | 0.0 |
| Bid Size | 100 |
| Book Value | 10.416 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.25 |
| Current Ratio | 2.792 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 27.38 |
| Day Low | 24.6 |
| Debt To Equity | 150.792 |
| Display Name | Pelthos Therapeutics |
| Earnings Call Timestamp End | 1,778,761,800 |
| Earnings Call Timestamp Start | 1,778,761,800 |
| Earnings Timestamp | 1,778,761,800 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 4.05 |
| Enterprise Value | 112,190,680 |
| Eps Current Year | -10.6625 |
| Eps Forward | -2.125 |
| Eps Trailing Twelve Months | -22.92 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 26.7725 |
| Fifty Day Average Change | -0.5224991 |
| Fifty Day Average Change Percent | -0.019516261 |
| Fifty Two Week Change Percent | 24.47257 |
| Fifty Two Week High | 37.5 |
| Fifty Two Week High Change | -11.25 |
| Fifty Two Week High Change Percent | -0.3 |
| Fifty Two Week Low | 16.5 |
| Fifty Two Week Low Change | 9.75 |
| Fifty Two Week Low Change Percent | 0.59090906 |
| Fifty Two Week Range | 16.5 - 37.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,708,093,800,000 |
| Float Shares | 1,394,603 |
| Forward Eps | -2.125 |
| Forward P E | -12.3529415 |
| Free Cashflow | -34,339,868 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 92 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.7516 |
| Gross Profits | 20,820,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.53775 |
| Held Percent Institutions | 0.35569 |
| Implied Shares Outstanding | 3,475,645 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,751,414,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina. |
| Long Name | Pelthos Therapeutics Inc. |
| Market | us_market |
| Market Cap | 91,235,680 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1803540075 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -51,589,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 92,278,374 |
| Number Of Analyst Opinions | 7 |
| Open | 27.0 |
| Operating Cashflow | -35,084,000 |
| Operating Margins | -1.20007 |
| Payout Ratio | 0.0 |
| Phone | 919 908 2400 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 26.25 |
| Post Market Time | 1,783,976,700 |
| Prev Name | Chromocell Therapeutics Corporation |
| Previous Close | 26.55 |
| Price Eps Current Year | -2.461899 |
| Price Hint | 2 |
| Price To Book | 2.5201612 |
| Price To Sales Trailing12 Months | 3.293588 |
| Profit Margins | -1.86235 |
| Quick Ratio | 1.747 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | -0.299999 |
| Regular Market Change Percent | -1.12994 |
| Regular Market Day High | 27.38 |
| Regular Market Day Low | 24.6 |
| Regular Market Day Range | 24.6 - 27.38 |
| Regular Market Open | 27.0 |
| Regular Market Previous Close | 26.55 |
| Regular Market Price | 26.25 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 41,779 |
| Return On Assets | -0.36453 |
| Return On Equity | -3.33843 |
| Revenue Per Share | 10.841 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,475,645 |
| Shares Percent Shares Out | 0.008 |
| Shares Short | 27,790 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 38,114 |
| Short Name | Pelthos Therapeutics Inc. |
| Short Percent Of Float | 0.0162 |
| Short Ratio | 1.27 |
| Source Interval | 15 |
| State | NC |
| Symbol | PTHS |
| Target High Price | 75.0 |
| Target Low Price | 48.0 |
| Target Mean Price | 57.71429 |
| Target Median Price | 55.0 |
| Total Cash | 31,976,000 |
| Total Cash Per Share | 9.2 |
| Total Debt | 52,931,000 |
| Total Revenue | 27,701,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -22.92 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 26.299515 |
| Two Hundred Day Average Change | -0.04951477 |
| Two Hundred Day Average Change Percent | -0.0018827256 |
| Type Disp | Equity |
| Volume | 41,779 |
| Website | https://pelthos.com |
| Zip | 27,703 |